Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma

Toxicology Letters

Volumn 230, Issue 3, 2014, Pages 467-478

  Mattes, W ^a   Davis, K ^b   Fabian, E ^d   Greenhaw, J ^c   Herold, M ^e   Looser, R ^e   Mellert, W ^d   Groeters, S ^d   Marxfeld, H ^d   Moeller, N ^f   Montoya Parra, G ^d   Prokoudine, A ^e   Van Ravenzwaay, B ^d   Strauss, V ^d   Walk, T ^e   Kamp, H ^d  

^a PharmPoint Consulting   (United States)

^b Toxicologic Pathology Associates   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d BASF SE   (Germany)

^e Metanomics GmbH   (Germany)

^f Metanomics Health GmbH   (Germany)

Author keywords

Hepatotoxicity; Metabolomic; Rat plasma

Indexed keywords

ATROPINE; BILIRUBIN; CAPTOPRIL; FLUTAMIDE; LAMIVUDINE; LIVER ENZYME; MANNITOL; METHOTREXATE; NEFAZODONE; NEOMYCIN; NEVIRAPINE; PARACETAMOL; PHENYTOIN; PROPYLTHIOURACIL; STREPTOMYCIN; STREPTOMYCIN SULFATE; VALPROIC ACID; VANCOMYCIN; ZIDOVUDINE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE MINERAL; CELL PROLIFERATION; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLUID INTAKE; FOOD INTAKE; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAHEPATIC CHOLESTASIS; KIDNEY TUBULE NECROSIS; LIVER CELL; LIVER CELL DAMAGE; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MALE; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOLOGY; PERITONITIS; PEROXISOME; PLASMA; RAT; STEROID METABOLISM; ANIMAL; BLOOD; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; LIVER; METABOLISM; PROCEDURES; TOXICITY; WISTAR RAT;

ANIMALS; ATROPINE; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FEMALE; FLUTAMIDE; LAMIVUDINE; LIVER; MALE; MANNITOL; METABOLOMICS; METHOTREXATE; NEOMYCIN; OXIDATIVE STRESS; PHENYTOIN; PROPYLTHIOURACIL; RATS; RATS, WISTAR; STREPTOMYCIN; TRIAZOLES; VALPROIC ACID; VANCOMYCIN; ZIDOVUDINE;

EID: 84910049085     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.07.021     Document Type: Article

References (59)

1. Andrade R.J., Lucena M.I., Kaplowitz N., Garcia-Munoz B., Borraz Y., Pachkoria K., Garcia-Cortes M., Fernandez M.C., Pelaez G., Rodrigo L., Duran J.A., Costa J., Planas R., Barriocanal A., Guarner C., Romero-Gomez M., Munoz-Yague T., Salmeron J., Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44:1581-1588.
2. Antoine D.J., Mercer A.E., Williams D.P., Park B.K. Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica 2009, 39:565-577.
3. Baldrick P. Safety evaluation to support first-in-man investigations II: toxicology studies. Regul. Toxicol. Pharmacol. 2008, 51:237-243.
4. Beger R.D., Sun J., Schnackenberg L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 2010, 243:154-166.
5. Boelsterli U.A., Redinbo M.R., Saitta K.S. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol. Sci. 2013, 131:654-667.
6. Boudonck K.J., Mitchell M.W., Nemet L., Keresztes L., Nyska A., Shinar D., Rosenstock M. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 2009, 37:280-292.
7. Campos A., Vasconcelos V. Molecular mechanisms of microcystin toxicity in animal cells. Int. J. Mol. Sci. 2010, 11:268-287.
8. Chen M., Vijay V., Shi Q., Liu Z., Fang H., Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 2011, 16:697-703.
9. Chen S.C., Barker S.M., Mitchell D.H., Stevens S.M., O'Neill P., Cunningham A.L. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection. Pathology 1992, 24:109-111.
10. Choi S., Lee A.K. Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc. Patient Saf. 2011, 3:107-119.
11. Chu K.M., Boulle A.M., Ford N., Goemaere E., Asselman V., van Cutsem G. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One 2010, 5:e9183.
12. Clarke C.J., Haselden J.N. Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol. Pathol. 2008, 36:140-147.
13. Coggon D.I., Martyn C.N. Time and chance: the stochastic nature of disease causation. Lancet 2005, 365:1434-1437.
14. Corsini A., Ganey P., Ju C., Kaplowitz N., Pessayre D., Roth R., Watkins P.B., Albassam M., Liu B., Stancic S., Suter L., Bortolini M. Current challenges and controversies in drug-induced liver injury. Drug Saf. 2012, 35:1099-1117.
15. Crissman J.W., Goodman D.G., Hildebrandt P.K., Maronpot R.R., Prater D.A., Riley J.H., Seaman W.J., Thake D.C. Best practices guideline: toxicologic histopathology. Toxicol. Pathol. 2004, 32:126-131.
16. D'Andrea G., Brisdelli F., Bozzi A. AZT: an old drug with new perspectives. Curr. Clin. Pharmacol. 2008, 3:20-37.
17. Deepa P.R., Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chem. Biol. Interact. 2003, 146:201-210.
18. Edwards I.R. Withdrawing drugs: nefazodone, the start of the latest saga. Lancet 2003, 361:1240.
19. El-Sayyad H.I., Ismail M.F., Shalaby F.M., Abou-El-Magd R.F., Gaur R.L., Fernando A., Raj M.H., Ouhtit A. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int. J. Biol. Sci. 2009, 5:466-473.
20. Ennulat D., Magid-Slav M., Rehm S., Tatsuoka K.S. Diagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat. Toxicol. Sci. 2010, 116:397-412.
21. Evered M.D., Robinson M.M. Increased or decreased thirst caused by inhibition of angiotensin-converting enzyme in the rat. J. Physiol. 1984, 348:573-588.
22. Faustman E.M., Omenn G. Risk assessment. Casarett and Doull's Toxicology 2008, 107-128. New York, McGraw-Hill. C.D. Klaassen (Ed.).
23. Gregus Z. Mechanisms of toxicity. Casarett and Doull's Toxicology: The Basic Science of Poisons 2008, 45-106. McGraw Hill, New York. C.D. Klaassen (Ed.).
24. Hoitsma A.J., Wetzels J.F., Koene R.A. Drug-induced nephrotoxicity. Aetiology clinical features and management. Drug Saf. 1991, 6:131-147.
25. Hoofnagle J.H., Serrano J., Knoben J.E., Navarro V.J. LiverTox: a website on drug-induced liver injury. Hepatology 2013, 57:873-874.
26. Horner S., Ryan D., Robinson S., Callander R., Stamp K., Roberts R.A. Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas. Regul. Toxicol. Pharmacol. 2013, 65:334-343.
27. ICH Steering Committee Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. vol. M3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2009, 31.
28. Jaeschke H., Gores G.J., Cederbaum A.I., Hinson J.A., Pessayre D., Lemasters J.J. Mechanisms of hepatotoxicity. Toxicol. Sci. 2002, 65:166-176.
29. Jaeschke H., McGill M.R., Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab. Rev. 2012, 44:88-106.
30. Kamp H., Fabian E., Groeters S., Herold M., Krennrich G., Looser R., Mattes W., Mellert W., Prokoudine A., Ruiz-Noppinger P., Strauss V., Walk T., Wiemer J., van Ravenzwaay B. Application of in vivo metabolomics to preclinical/toxicological studies: case study on phenytoin-induced systemic toxicity. Bioanalysis 2012, 4:2291-2301.
31. Ma R.C., Kong A.P., Chan N., Tong P.C., Chan J.C. Drug-induced endocrine and metabolic disorders. Drug Saf. 2007, 30:215-245.
32. Masur H., Whelton P.K., Whelton A. Neomycin toxicity revisited. Arch. Surg. 1976, 111:822-825.
33. Matheson G.K., Knowles A., Guthrie D., Gage D., Weinzapfel D., Blackbourne J. Actions of serotonergic agents on hypothalamic-pituitary-adrenal axis activity in the rat. Gen. Pharmacol. 1997, 29:823-828.
34. Mattes W.B., Kamp H.G., Fabian E., Herold M., Krennrich G., Looser R., Mellert W., Prokoudine A., Strauss V., van Ravenzwaay B., Walk T., Naraoka H., Omura K., Schuppe-Koistinen I., Nadanaciva S., Bush E.D., Moeller N., Ruiz-Noppinger P., Piccoli S.P. Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling. BioMed. Res. Int. 2013, 2013:12.
35. Morrell M.J. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003, 44(Suppl. 4):11-20.
36. Nelson A.A., Radowski J.L., Hagan E.C. Renal and other lesions in dogs and rats from intramuscular injection of neomycin. Fed. Proc. 1951, 10:366-367.
37. Omar R.F., Gourde P., Desormeaux A., Tremblay M., Beauchamp D., Bergeron M.G. In vivo toxicity of foscarnet and zidovudine given alone or in combination. Toxicol. Appl. Pharmacol. 1996, 139:324-332.
38. Peters T.S. Do preclinical testing strategies help predict human hepatotoxic potentials?. Toxicol. Pathol. 2005, 33:146-154.
39. Pillans P.I., Koopowitz A. Captopril-associated agranulocytosis. A report of 3 cases. S Afr. Med. J. 1991, 79:399-400.
40. Ragni M.V., Miller B.J., Whalen R., Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am. J. Hematol. 1992, 40:176-182.
41. Rouquie D., Friry-Santini C., Schorsch F., Tinwell H., Bars R. Standard and molecular NOAELs for rat testicular toxicity induced by flutamide. Toxicol. Sci. 2009, 109:59-65.
42. Russmann S., Kullak-Ublick G.A., Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 2009, 16:3041-3053.
43. Russo M.W., Galanko J.A., Shrestha R., Fried M.W., Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004, 10:1018-1023.
44. Senior J.R. Monitoring for hepatotoxicity: what is the predictive value of liver function tests?. Clin. Pharmacol. Ther. 2009, 85:331-334.
45. Smythe M.A., Umstead G.S. Phenytoin hepatotoxicity: a review of the literature. DICP 1989, 23:13-18.
46. Stewart D.E. Hepatic adverse reactions associated with nefazodone. Can. J. Psychiatry 2002, 47:375-377.
47. Tortorella C., Guidolin D., Petrelli L., De Toni R., Milanesi O., Ruga E., Rebuffat P., Bova S. Prolonged zidovudine administration induces a moderate increase in the growth and steroidogenic capacity of the rat adrenal cortex. Int. J. Mol. Med. 2009, 23:799-804.
48. Travlos G.S., Morris R.W., Elwell M.R., Duke A., Rosenblum S., Thompson M.B. Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats. Toxicology 1996, 107:17-29.
49. Tsekes G., Chrysos G., Douskas G., Paraskeva D., Mangafas N., Giannakopoulos D., Papanikolaou M., Georgiou E., Lazanas M.C. Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med. 2002, 3:85-90.
50. Vaidya V.S., Ozer J.S., Dieterle F., Collings F.B., Ramirez V., Troth S., Muniappa N., Thudium D., Gerhold D., Holder D.J., Bobadilla N.A., Marrer E., Perentes E., Cordier A., Vonderscher J., Maurer G., Goering P.L., Sistare F.D., Bonventre J.V. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol. 2010, 28:478-485.
51. van Ravenzwaay B., Coelho-Palermo Cunha G., Fabian E., Herold M., Kamp H., Krennrich G., Krotzky A., Leibold E., Looser R., Mellert W., Prokoudine A., Strauss V., Tretheway R., Walk T., Wiemer J. The use of metabolomics in cancer research. An Omics Perspective of Cancer 2010, 141-166. Springer science+media B. V, Dordrecht. W.C.S. Cho (Ed.).
52. van Ravenzwaay B., Cunha G.C., Leibold E., Looser R., Mellert W., Prokoudine A., Walk T., Wiemer J. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol. Lett. 2007, 172:21-28.
53. van Ravenzwaay B., Herold M., Kamp H., Kapp M.D., Fabian E., Looser R., Krennrich G., Mellert W., Prokoudine A., Strauss V., Walk T., Wiemer J. Metabolomics: a tool for early detection of toxicological effects and an opportunity for biology based grouping of chemicals-from QSAR to QBAR. Mutat. Res. 2012, 746:144-150.
54. Wang J., Reijmers T., Chen L., van der Heijden R., Wang M., Peng S., Hankemeier T., Xu G., van der Greef J. Systems toxicology study of doxorubicin on rats using ultra performance liquid chromatography coupled with mass spectrometry based metabolomics. Metabolomics 2009, 5:407-418.
55. Weingand K., Brown G., Hall R., Davies D., Gossett K., Neptun D., Waner T., Matsuzawa T., Salemink P., Froelke W., Provost J.P., Dal Negro G., Batchelor J., Nomura M., Groetsch H., Boink A., Kimball J., Woodman D., York M., Fabianson-Johnson E., Lupart M., Melloni E. Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. Fundam. Appl Toxicol 1996, 29:198-201.
56. Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006, 11:694-703.
57. Wysowski D.K., Fourcroy J.L. Flutamide hepatotoxicity. J. Urol. 1996, 155:209-212.
58. Yagmurca M., Bas O., Mollaoglu H., Sahin O., Nacar A., Karaman O., Songur A. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch. Med. Res. 2007, 38:380-385.
59. Zimmerman H.J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver 1999, 789. Lippincott Williams & Wilkins, Philadelphia.